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Background: The preoperative characterization of thyroid nodules is a challenge for the clinicians. Fine-needle
aspiration (FNA) is the commonly used pre-operative technique for diagnosis of malignant thyroid tumor. However,
many benign lesions, with indeterminate diagnosis following FNA, are referred to surgery. There is an urgent need
to identify biomarkers that could be used with the FNA to distinguish benign thyroid nodules from malignant
tumors. The purpose of the study is to examine the level of expression of the helicase-like transcription factor (HLTF)
in relation to neoplastic progression of thyroid carcinomas.
Methods: The presence of HLTF was investigated using quantitative and semi-quantitative immunohistochemistry
in a series of 149 thyroid lesion specimens. Our first clinical series was composed of 80 patients, including 20
patients presenting thyroid adenoma, 40 patients presenting thyroid papillary carcinoma, 12 patients presenting
thyroid follicular carcinoma and 8 patients presenting anaplastic carcinoma. These specimens were assessed
quantitatively using computer assisted microscopy. Our initial results were validated on a second clinical series
composed of 40 benign thyroid lesions and 29 malignant thyroid lesions using a semi-quantitative approach.
Finally, the HLTF protein expression was investigated by Western blotting in four thyroid cancer cell lines.
Results: The decrease of HLTF staining was statistically significant during thyroid tumor progression in terms
of both the percentage of mean optical density (MOD), which corresponds to the mean staining intensity
(Kruskall-Wallis: p < 0.0005), and the labelling index (LI), which corresponds to the percentage of immunopositive
cells (Kruskall-Wallis: p < 10−6). Adenomas presented very pronounced nuclear HLTF immunostaining, whereas
papillary carcinomas exhibited HLTF only in the cytoplasm. The number of HLTF positive nuclei was clearly higher
in the adenomas group (30%) than in the papillary carcinomas group (5%).
The 115-kDa full size HLTF protein was immunodetected in four studied thyroid cancer cell lines. Moreover, three
truncated HLTF forms (95-kDa, 80-kDa and 70-kDa) were also found in these tumor cells.
Conclusions: This study reveals an association between HLTF expression level and thyroid neoplastic progression.
Nuclear HLTF immunostaining could be used with FNA in an attempt to better distinguish benign thyroid nodules
from malignant tumors.
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Thyroid cancer is the most common malignant endocrine
tumor with an estimated annual incidence of 122,803
cases worldwide [1]. Well-differentiated thyroid carci-
nomas (papillary and follicular carcinomas) have an excel-
lent prognosis, with 85 to 90% cure rates thanks to early
detection and appropriate treatment. Until now, fine-
needle aspiration (FNA) was the most commonly used
pre-operative technique for diagnosis of a malignant thy-
roid tumor. However, using ultrasound-guided FNA, this
technique showed inconclusive biopsy results in 10-20%
of all cases, even with the best hands of radiologist and/or
pathologist. Thus, there is an urgent need to identify new
biomarkers that could be used in conjunction with
the FNA to distinguish benign thyroid nodules from
malignant tumors. Such biomarkers may provide crucial
knowledge about the biology of well-differentiated thyroid
cancers and, most likely, new directions for targeted
therapies.
Helicase-like Transcription Factor (HLTF) is a SWI/SNF
(mating-type switching/sucrose non-fermenting) protein
that presents 7 DNA helicase domains that use the energy
of ATP hydrolysis to remodel chromatin in a variety of
cellular processes; it was initially characterized for its
DNA binding and transcriptional activity [2,3]. HLTF was
later shown to act as an E3 ubiquitin ligase implicated in
post-replication DNA repair by polyubiquitination of pro-
liferating cell nuclear antigen (PCNA) and to be recruited
to chromatin by the BRCA1 tumor suppressor together
with translesion synthesis polymerases [4-7]. HLTF, as well
as its yeast Rad5 ortholog, promote the repair of gaps
formed at stalled replication forks on damaged DNA [8].
The inactivation of HLTF induces an elevated level of
chromosome breaks and fusions in mouse embryonic
fibroblasts after treatment with alkylating agents [5] and
increases the sensitivity of cells submitted to DNA da-
maging agents. In agreement with a post-replicative func-
tion, HLTF inactivation in a transgenic mouse disrupts
cell cycle progression at the G2-M transition both in heart
and brain cells [9,10].
Several studies have demonstrated that the HLTF pro-
moter is hypermethylated in human colorectal [11-19],
gastric [13,20,21], esophageal [13,22] and uterine cancers
[23], suggesting that HLTF silencing may play a crucial
role in cancer. Moreover, H. Ding’s group confirmed a
tumor suppressor function by mouse transgenesis: HLTF
deficiency in Apc−/+ mice induced the transition from
colon adenoma to carcinoma with high chromosomal in-
stability [24]. In a different model, HLTF induction was
detected very early in small pre-neoplastic buds of ham-
ster kidney tumors induced by diethylstilbestrol [25]. Re-
cently, we studied the immunohistochemical expression
of HLTF in relation to head and neck squamous cell car-
cinoma (HNSCC) tumor progression. We showed thatHLTF expression increases significantly when comparing
carcinomas to normal epithelia or dysplasias [26]. More-
over, high levels of HLTF expression were found to be
associated with rapid recurrence rates in a series of 100
hypopharyngeal squamous cell carcinomas (SCC) [26].
We characterized the HLTF mRNAs from HeLa cells
by RT-PCR and identified 6 protein forms. One of these
forms, the 95-kDa HLTF, was detected along with the
115-kDa full-length protein in both head and neck SCC
biopsies. The 95-kDa variant did not contain the 3
carboxyl-terminal helicase domains that are involved in
DNA repair [26]. Similarly, the immunoexpression of
the 115-kDa full-size HLTF protein increased during
carcinogenesis of the uterine cervix but was replaced by
truncated forms (95 or 83-kDa) in squamous cell carci-
noma [27]. These observations suggested that HLTF ex-
pression could also be altered in thyroid carcinogenesis.Methods
The first part of the study was conducted using thyroid
tumor surgical specimens. Immunohistochemical HLTF
expression was studied in a clinical series of 149 patients
with benign and malignant thyroid lesions. The pa-
thological area was analyzed quantitatively by computer
assisted morphometry in 80 cases (in addition to a nuclear
assessment) and semi-quantitatively in 69 additional cases.
These data were submitted to statistical analysis (Figure 1).
The second part of the study was performed using thy-
roid cancer cell lines (B-CPAP, TPC-1, FTC133, 8505C
and HeLa). Immunocytochemical HLTF expression was
examined by immunofluorescence and Western blotting
(Figure 1).Patient’ characteristics
The immunohistochemical HLTF expression was first
studied in a clinical series of 80 patients (23 males and 57
females), including 20 patients with thyroid adenoma, 40
patients presenting with thyroid papillary carcinoma, 12
patients presenting with thyroid follicular carcinoma and 8
patients presenting with anaplastic carcinoma. This series
was selected by a pathologist (Prof. M. Remmelink,
Erasme hospital, Department of Pathology, ULB, Belgium),
and after her delineation, the pathological area was ana-
lyzed quantitatively by computer-assisted morphometry.
For the second part, we extended our analysis to a series
of 40 patients (9 males and 60 females) with benign thy-
roid lesions, including 10 colloid nodules, 16 follicular ad-
enomas, 7 Hashimoto’s thyroiditis, and 7 Grave’s disease,
and to a series of 29 patients with malignant thyroid le-
sions including 17 papillary carcinomas and 12 follicular
variant of papillary carcinomas. These series were selected
by the same pathologist (Prof. M. Remmelink, Erasme
hospital, Department of Pathology, ULB, Belgium), and
Figure 1 Experimental flow diagram. The immunohisto/cytochemical HLTF expression was studied in a clinical series of 149 patients (with benign
and malignant thyroid lesions) and on thyroid cancer cell lines.
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Ethics Statement
These clinical studies were approved by the Faculty of
Medicine and Pharmacy (University of Mons, Belgium)
ethics committee (OM 004). A written informed consent
was obtained from all patients.
Anti-HLTF antibodies
Two human HLTF protein forms are expressed from the
same open reading frame and differ only in the transla-
tion start site (Met1 or Met123) [2]. The ART2 rabbit
anti-serum was raised against a peptide in the HLTF
amino-terminal sequence specific of the full length Met1
form, as previously described in Debauve et al. [25].
The anti-COOH rabbit serum (Eurogentec) is specific
to the wild type HLTF proteins (Met1 and Met123) and
was raised against a peptide (CFGTKKPNADEMKQAX)
that is missing in the HLTF truncated variants.
The anti-HLTF rabbit serum (HPA015284, Sigma) de-
tects all HLTF protein forms and was raised against a
peptide extending from residues 164 to 300 (LKKHG…
MGLGK).
Cell Culture
Four cell lines derived from human thyroid cancers
were studied: B-CPAP and TPC-1 derived from papillary
carcinoma (Dr. C.Paulin, Laboratory of Anatomy and
Cytology-Pathology, University of Lyon, Lyon, France and
Prof. C.Maenhout, IRIBHM ULB, Brussels, Belgium, re-
spectively), FTC-133 derived from follicular carcinoma
(Dr. Köhrle, Institute of Experimental Endocrinology of
the Charité, Humboldt University, Berlin, Germany) and
8505C derived from anaplastic carcinoma (Dr. Akiyama,
Radiation Effects Research Foundation, Hiroshima). The
HeLa cell line was used as the positive control. HeLa cells
are derived from cervical carcinoma and are routinelycultivated in the laboratory of Molecular Biology (UMons).
The cell lines HeLa, FTC-133, TPC-1, B-CPAP and 8505C
were grow in Dulbecco’s Modified Essential Medium–F12
(DMEM-F12, Lonza) and RPMI 1640 (Lonza) with 10%
fetal bovine serum (FBS, PAA Laboratories) and 1% anti-
biotics and antimycotics (PAA Laboratories). The cells
were incubated at 37°C with 5% CO2. The culture medium
was changed once every 3 days. For routine subculture
and cell plating in preparation for immunofluorescence
studies, cells were detached by incubation with Accutase
(PAA Laboratories), resuspended and counted using a
hemocytometer.
Immunofluorescence Staining of Cultured Cells
Six-well culture plates containing sterile round glass cov-
erslips were seeded at a density of 5x105 cells/well and
grown for 24 h. Cell cultures were rinsed with phosphate-
buffered saline (PBS: 0.04 M Na2HPO4, 0.01 M KH2PO4
and 0.12 M NaCl, pH 7.4) and fixed in 4% paraformalde-
hyde for 10 min at 4°C and 5 min at room temperature
(RT). The fixed cells were rinsed in PBS and blocked by
incubation with bovine serum albumin (PBS plus 0.2%
Triton X-100 and 5% BSA) for 30 min at RT. The fixed
cells were incubated in the ART2 primary antibody di-
luted 1/100 in the blocking buffer for 1 h at RT, rinsed in
PBS and incubated with Alexa Fluor 555 goat anti-rabbit
IgG (Invitrogen) for 30 min. The immunostained sections
were rinsed in PBS, mounted in Vectashield (Vector
Laboratories), examined under a LeitzOrthoplan fluo-
rescence microscope (Ploem system) and representative
fields were recorded with a digital camera (Leica DC
300 F). Controls for the immunostaining specificity in-
cluded the omission of the primary antibody or the substi-
tution of non-immune sera for the primary antibodies.
The specificity of anti-HLTF immunostaining was also ex-
amined with primary antibodies previously incubated with
the synthetic peptide used as an antigen. In each case,
these controls were negative (data not shown).
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Tumors
All tumor samples were fixed for 24 h in 10% buffered for-
maldehyde, dehydrated and then embedded in paraffin.
Immunochemistry was performed on 5 μm-thick sections
that were mounted on silane-coated glass sides. Before ini-
tiating the immunochemistry, tissue sections were briefly
exposed to microwave pre-treatment in a 0.01 M citrate
buffer (pH 6.2) for 2 × 5 min at 900 W. The sections were
then incubated in a 0.06% hydrogen peroxide solution for
4 min to block endogenous peroxidase activity, rinsed in
PBS and successively exposed for 5 min to solutions con-
taining avidin (0.1 mg/ml PBS) and biotin (0.1 mg/ml
PBS) to avoid false-positive staining reactions from en-
dogenous biotin. After a washing step with PBS, the sec-
tions were incubated for 15 min with a solution of 0.5%
casein in PBS and sequentially exposed at RT to solutions
of i) specific primary anti-HLTF antibody (1/50); ii) corre-
sponding biotinylated secondary antibody (polyclonal goat
anti-rabbit IgG, 1/50, Vector Laboratories, Burlingame,
CA); and iii) avidin- biotin-peroxidase complex (ABC Kit,
Vector Laboratories, Burlingame, CA). The incubation
steps were alternated with washing steps to remove
unbound proteins. Antigen-dependent presence of the
peroxidase complex in the sections was visualized by incu-
bation with chromogenic substrates containing diamino-
benzidine and H2O2. After rinsing, the sections were
counterstained with Luxol fast blue and mounted with a
synthetic medium. To exclude antigen-independent stain-
ing, the incubation step with primary antibodies was omit-
ted from the protocol in negative controls. In all cases,
these controls were negative (data not shown).
Immunohistochemical Quantitative Analysis using a
Computer-assisted microscopy
After the immunohistochemical steps, the levels of HLTF
protein expression were quantitatively determined in our
initial clinical series using a computer-assisted KS 400 im-
aging system (Carl Zeiss Vision, Hallbergmoos, Germany)
connected to a Zeiss Axioplan microscope. For each sec-
tion, 10 fields were analyzed at a 20X magnification and a
picture was recorded for each of them by the ProgRes-
CapturePro 2.1 program. The morphometric analysis was
focused on selected pathological areas where two variables
were measured: the labelling index (LI) and the mean op-
tical density (MOD). The median was calculated for each
section and for each tumor type.
Nuclear assessment by Optical Microscopy
For each specimen, 10 fields were analyzed at a 40X
magnification to count the immunopositive nuclei and
also the total number of nuclei in a gate of 0.084 mm2.
The mean of positive nuclei was assessed for each
specimen.Immunohistochemical Semi-quantitative Analysis
After the immunohistochemical steps, the levels of HLTF
expression were semi-quantitatively determined on the
second clinical series in collaboration with a pathologist
(M.R) using an optical microscope (Leitz). The mean in-
tensity (MI) was defined as follows: 0 (negative), 1 (low), 2
(moderate), and 3 (strong). The percentages of immuno-
positive tissue areas (Labelling index, LI) were categorized
as follows: 0 (0% positive cells), 1 (1-25%), 2 (26-75%), and
3 (76-100%).
Western blotting
Total cell, nuclear and cytoplasmic extracts were used for
all cell lines. To obtain total cell extracts, cells were reco-
vered on ice with a scraper in 1 ml of PBS. The cell sus-
pension was centrifuged at 4000 rpm for 5 min at 4°C. We
resuspended the pellet in 100 μl of lysis buffer (BugBuster
Protein Extraction Reagent, Novagen) for protein extrac-
tion. Nuclear and cytoplasmic extractions were performed
using the NE-PER Nuclear and Cytoplasmic Extraction kit
(Thermo Fisher Scientific) according to the manufac-
turer’s instructions.
Cells were homogenized at 4°C in hypertonic buffer
(Tris 50 mM pH 7, NaCl 500 mM and NP40 0.1%) with
added anti-proteases (Protease Inhibitor Cocktail, Sigma)
and 1 mM DTT. Protein concentrations were measured
using the Bio-Rad protein assay (BioRad Laboratories).
40 μg (for nuclear and cytoplasmic extracts) or 60 μg (for
total cell extracts) of protein were diluted in 5 μl 4X LDS
sample buffer (NuPAGE LDS sample buffer 4X, Invitro-
gen), 1 μl 20X reducing reagent (Fermentas) and up to
20 μl water, heated to 95°C for 5 min and separated
by 4-12% PAGE-SDS (NuPAGE 4%-12% Bis-Tris Gel,
Novex). After electrophoresis, the proteins were electro-
transferred from the gel onto a nitrocellulose membrane
(Hybond ECL, Amersham Pharmacia Biotech) using an
electrophoretic transfer cell (Bio-Rad) at 260 mA for 1 h
45 min at 4°C. The transfer efficiency was controlled by
Ponceau red staining (Ponceau S Solution, Sigma). Non-
specific protein binding sites on the membrane were
blocked by incubation with PBS 5% non-fat milk (Bio-
Rad) for 1 h at RT. The membrane was incubated at 4°C
overnight in the anti-HLTF primary antibody (Sigma)
diluted 1/500 (for nuclear and cytoplasmic extracts) or
1/1000 (for total cell extracts) in the blocking buffer. After
incubation, the membrane was washed three times with
PBS and incubated for 1 h at RT with HRP-conjugated
goat anti-rabbit IgG antibodies (Amersham Pharmacia
Biotech) diluted 1/5000 in 0.5% Albumin bovine fraction
V (BSA, MP Biomedicals). After treatment with Super
Signal West Femto Chemiluminescent Substrate (Thermo
Scientific), the membrane was exposed for 15 min on a
photosensitive film (Hyperfilm ECL, Amersham Pharma-
cia Biotech). Molecular weight markers were analyzed in
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Proteins, Fermentas).
Statistical Analysis
Independent groups of quantitative and semi-quantitative
data were compared using the nonparametric Kruskall-
Wallis test (for comparison of more than two groups). In
the case of more than two groups, post-hoc tests (Dunn
procedure) were used to compare pairs of groups (to avoid
multiple comparison effects).
Results
HLTF immunostaining decreases with tumor progression
and shifts from the nucleus to the cytoplasm
The first aim of our study was to quantitatively investigate
HLTF expression in a series of 80 thyroid tumors. More-
over, the HLTF sub-location (nuclear staining) was also
assessed by cell counting. In adenomas, the HLTF staining
was moderate in the cytoplasm, but a pronounced nuclear
staining was clearly observed (Figure 2A, B). In contrast,
in papillary carcinomas, the HLTF staining was limited to
the cytoplasm (Figure 2D, E), whereas follicular and ana-
plastic carcinomas exhibited weak cytoplasmic and nu-
clear immunostaining (Figure 2C, F, respectively).
To clearly present our data, we first compared all groups
(Adenomas: Ad; Papillary Carcinomas: PC; Follicular Car-
cinomas: FC; and Anaplastic carcinomas: AC) using a
nonparametric Kruskall-Wallis test (Figure 3). The de-
crease in HLTF staining was statistically significant duringFigure 2 Immunohistochemical staining of HLTF (ART2 rabbit serum)
carcinoma, D-E: papillary carcinoma and F: anaplastic carcinoma. The scale bathyroid tumor progression in terms of both MOD, which
corresponds to the mean staining intensity (Kruskall-
Wallis: p < 0.0005, Figure 3A), and the LI, which cor-
responds to the percentage of immunopositive cells
(Kruskall-Wallis: p < 10−6, Figure 3B). Using a post-hoc
comparison for pairs of groups, we observed that HLTF
expression decreased when comparing adenomas to
anaplastic carcinomas (MOD: p = 0.03, Figure 3A; LI:
p = 0.05, Figure 3B), adenomas to follicular carcinomas
(LI: p = 0.02, Figure 3B), papillary carcinomas to follicular
carcinomas (MOD: p = 0.02, Figure 2A; LI: p = 0.000003,
Figure 2B) and papillary carcinomas to anaplastic car-
cinomas (MOD: p = 0.002, Figure 3A; LI: p = 0.00006,
Figure 3B).
In addition, the percentage of HLTF positive nuclei dif-
fered significantly among the 4 tumor groups (Kruskal-
Wallis p < 10−6, Figure 3C). More precisely, this difference
is significant when comparing adenomas to papillary car-
cinomas (p = 0.000004, post-hoc test, Figure 3C). Indeed,
the median value of the number of HLTF positive nuclei
in the adenoma group (30%) is clearly higher than that in
the papillary carcinoma group (5%).
HLTF immunostaining is detected in benign thyroid
lesions
Figure 4A-F illustrates the HLTF immunohistochemical
expression in a series of 40 benign thyroid lesions in-
cluding 10 with colloid nodules (CN), 16 with adenomas
(Ad), 7 with Hashimoto’s thyroiditis (HT) and 7 within benign and malignant thyroid tumors. A-B: adenoma, C: follicular
r is 25 μm (B and E) and 50 μm (A, C, D and F).
Figure 3 Statistical analysis of HLTF staining in a series of 4 groups of thyroid tumors. Ad: thyroid adenomas, PC: papillary carcinomas, FC:
follicular carcinomas and AC: anaplastic carcinomas. The immunohistochemical expression was assessed quantitatively using the MOD (A), LI (B)
and the percentage of positive nuclei (C). The threshold of significance associated with the global multigroup comparison (Kruskal-Wallis test) is
located in the higher right corner. Horizontal arrows represent the post-hoc comparison for the pairs of groups with corresponding p-values.
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HLTF is localized in both the nucleus and the cytoplasm
of follicular cells, but with a significantly higher staining
intensity at the nuclear level (Figure 4A, B). In Hashimo-
to’s thyroiditis (HT) and Grave’s disease (GD), a decrease
in nuclear staining was observed (Figure 4C, D, respec-
tively). All of the specimens were assessed using a semi-
quantitative analysis with one pathologist (MR) because
the quantitative assessment could not be proposed in a
routine examination. We compared all groups (CN, Ad,
HT, GD) using a nonparametric Kruskall-Wallis test and
obtained a significant difference in terms of both the
percentage of the mean immunopositive nuclei (LI nuc:
p = 0.007; Kruskal-Wallis) (Figure 4E) and the mean stain-
ing intensity of the immunopositive nuclei (MI nuc:
p = 0.02; Kruskal-Wallis) (Figure 4F). These two para-
meters were decreased in Hashimoto’s thyroiditis (HT)
and Grave’s disease (GD) when compared to colloid no-
dules (CN) and adenomas (Ad). Then, using a post-hoccomparisons for pairs of groups, we determined that the
percentage of immunopositive epithelial cells was higher
in colloid nodules than in Grave’s Disease (LI nuc:
p = 0.04, post- hoc test) (Figure 4A, D, E). We also observed
that the staining intensity of the immunopositive epithelial
cells of colloid nodules was stronger than that in Hashimo-
to’s thyroiditis, where the nuclear staining was moderate
(MI nuc: p = 0.04, post-hoc test) (Figure 4A, C, F). These
results show that the HLTF expression level decreases in
thyroid autoimmune diseases, which can develop into
thyroid carcinomas, suggesting a potential role in early
diagnosis.
HLTF nuclear immunostaining profile during thyroid
tumor progression
The immunohistochemical expression of HLTF was inves-
tigated in a series of normal thyroid tissue as well as in be-
nign and malignant lesions, more specifically, 4 normal
thyroid tissue (N), 10 colloid nodules (CN), 16 adenomas
Figure 4 Immunohistochemical staining of HLTF in benign thyroid lesions and statistical analysis of HLTF staining in a series of 4
groups of benign thyroid lesions. (A-D) A: colloid nodule, B: adenoma, C: Hashimoto’s Thyroiditis and D: Graves’ Disease. The scale bar is 50 μm.
(E-F) CN: colloid nodules, Ad: follicular adenomas HT: Hashimoto’s Thyroiditis and GD: Graves’ Diseases. The immunohistochemical expression was
semi-quantitatively assessed in the nuclear compartment using (E) the LI (LI nuc) and (F) the MI (MI nuc). The threshold of significance associated with
the global multigroup comparison (Kruskal-Wallis test) is located in the higher right corner. Horizontal arrows represent the post-hoc comparison for
the pairs of groups, with corresponding p-values.
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(GD), 17 papillary carcinomas (PC) and 12 follicular va-
riant of papillary carcinomas (FVPC). In adenomas, HLTF
was localized in both the nucleus and the cytoplasm of
cells but with significantly higher staining intensity at the
nuclear level (Figure 5A). In papillary carcinomas, the
HLTF protein was detected in both compartments but
with a more pronounced staining at the nuclear periphery
(Figure 5B). The intensity of nuclear staining by our anti-
HLTF antibody was compared between these 7 groups
for which a significant difference was detected (MI nuc:
p < 10−6, Kruskal-Wallis) (Figure 5C). Post-hoc compari-
sons detected a significant difference between papillary
carcinomas and normal tissue (MI nuc: p = 0.02; post-hoc
test) and adenomas (MI nuc: p = 0.0002; post-hoc test)
and colloid nodules (MI nuc: p = 0.0002; post-hoc test)
(Figure 5C). We also observed a significant difference
when we compared FVPC with adenomas (MI nuc:p = 0.003) or colloid nodules (MI nuc: p = 0.002) (Figure 5C).
The intensity of the HLTF nuclear staining was strong in
adenomas (MI nuc: median = 2.5) and decreased in papil-
lary carcinomas (MI nuc: median = 1). These results cor-
roborate the first observation in which HLTF expression
decreased during thyroid tumor progression with a gra-
dual shift of HLTF staining from the nucleus to the cyto-
plasm in malignant cells.
Truncated HLTF protein forms are expressed in adenomas
and papillary carcinomas
HLTF immunohistochemical expression was investigated
in biopsies of adenomas and papillary carcinomas using
two different anti-HLTF antibodies. The ART2 serum
targets the amino-terminal domain of full-length HLTF
and two truncated HLTF forms (83- and 95- kDa) [26],
whereas the anti-COOH serum targets the carboxy-
terminal domain of wild-type HLTF that is missing in
Figure 5 Immunohistochemical staining of HLTF in benign and malignant thyroid tumors and statistical analysis of HLTF staining in
benign and malignant thyroid lesions. (A-B) A: follicular adenoma and B: papillary carcinoma. The scale bar is 50 μm. (C) N: normal tissues, Ad:
adenomas, HT: Hashimoto’s Thyroiditis, GD: Graves’ Diseases, CN: colloid nodules, PC: papillary carcinomas and FVPC: follicular variant of papillary
carcinomas. The immunohistochemical expression was semi-quantitatively assessed in the nuclear compartment using the MI (MI nuc). The threshold
of significance associated with the global multigroup comparison (Kruskal-Wallis test) is located in the higher right corner. Horizontal arrows represent
the post-hoc comparison for the pairs of groups, with corresponding p-values.
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antibody, HLTF was detected in both the nucleus and
the cytoplasm of follicular cells in adenomas (Figure 6A).
In papillary carcinomas, the staining was limited to the
cytoplasm (Figure 6C). By contrast, with the anti-COOH
antibody, HLTF staining was abolished both in aden-
omas and papillary carcinomas (Figure 6B, D), de-
monstrating the expression of truncated forms that lack
DNA repair ability.
HLTF staining pattern in thyroid cancer cell lines
We also studied the expression of HLTF protein by
immunocytofluorescence in 3 different transformed thy-
roid cell lines, B-CPAP, FTC-133 and 8505C, derived
from human papillary carcinoma, follicular carcinoma
and anaplastic carcinoma, respectively. The rabbit anti-
serum (ART2) specific for the HLTFMet1 variant was
used to determine the localization of HLTF in these
cells. HLTF expression was exclusively localized to the
nuclear compartment in all cell lines (Figure 7A-C).
We also determined the molecular size of the HLTF
protein by Western blotting followed by immunodetection
in these cell lines. HeLa cells were used as a positivecontrol because the cancer-associated truncated HLTF
protein variants were discovered in these cells [26]. In
total cell extracts, a band was detected at approximately
120-kDa in TPC-1, FTC-133, 8505C and HeLa cells
(Figure 7D; lanes 1, 3–5). These signals correspond to the
HLTF wild-type full-length protein (HLTFMet1). In
addition, a second band at 95-kDa, which corresponds to
the HLTFMet1ΔB variant, was observed in the TPC1,
FTC133 and 8505C thyroid cell lines (Figure 7D; lanes 1,
3–4). Finally, a band at ~80-kDa corresponding to the
HLTFMet1ΔA variant was detected in the TPC-1 and
FTC-133 thyroid cell lines (Figure 7D; lanes 1 and 3). In
the nuclear extracts, the ~120-kDa band was observed in
all of the cell lines except for BCPAP (Figure 7E; lanes 1,
3–5). The 95-kDa band was observed in FTC133, 8505C
and HeLa cells (Figure 7E; lanes 3–5). We also observed a
band at 80-kDa in FTC-133 cells (Figure 7E; lane 3).
Finally, a protein was detected at 70-kDa in all cell lines,
which may correspond to the HLTFMet123ΔA form, i.e.,
the translation initiation at the Met 123 codon and the
carboxyl-terminal truncation of 274 residues (Figure 7E;
lanes 1–5). In the cytoplasmic extracts, two bands were
detected at 120- and 95-kDa in all cell lines (Figure 7F,
Figure 6 Immunodetection of truncated HLTF forms lacking the carboxy-terminal domain. Immunohistochemical detection of HLTF using
rabbit antisera directed against the amino (ART2) or carboxy-terminal (anti-COOH) domains of the wild type protein on a biopsy of a follicular
adenoma (Ad, A-B) or a papillary carcinoma (PC, C-D). The scale bar is 100 μm.
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60-kDa band that does not correspond to any known
HLTF protein variant (Figure 7D-F; lanes 1–5).Discussion
The present study shows for the first time that follicular
adenomas present specific nuclear HLTF immunostaining
(using the ART2 rabbit anti-serum recognizing the HLTF
wild type protein as well as the two HLTF variants,
HLTFMet1ΔA and HLTFMet1ΔB), whereas papillary car-
cinomas exhibit cytoplasmic expression. This observation
has been confirmed in a second clinical series of benign
and malignant thyroid lesions, allowing us to propose
HLTF as a new potential marker of follicular adenomas.
This observation could be of major interest for FNAB
diagnosis in pathology. In fact, both parameters, LI and
MOD, could also be assessed on smeared cells from FNA,
but this immunohistochemical quantitative analysis re-
quires computer-assisted microscopy, which is not avail-
able in all pathology departments. In this context, we
propose further testing of HLTF as a new potential marker
of follicular adenomas on FNA using a threshold of 30%
HLTF-positive nuclei. In such case, the pathologist could
perform a semi-quantitative assessment of HLTF-positive
nuclei on smeared cells.Concerning the difficult differential diagnosis of follicular
adenomas from follicular carcinomas, our study showed
that HLTF staining was moderate in the cytoplasm and
pronounced in the nuclei of follicular adenomas, whereas
follicular carcinomas exhibited weak cytoplasmic and
nuclear immunostaining. Using quantitative analysis, we
demonstrated that HLTF expression decreased significantly
when comparing follicular adenomas to follicular car-
cinomas. However, our results are preliminary, and HLTF
expression should be studied in a larger series of follicular
adenomas versus carcinomas.
Moreover, our in vivo study revealed that the expres-
sion of one or more truncated HLTF protein variants
(HLTFMet1ΔA and HLTFMet1ΔB) was associated with
thyroid tumorigenesis. This observation is in agreement
with our previous study, which showed that cervical can-
cers exhibited a significant increase in HLTF expression
from normal epithelia to invasive squamous cell carcin-
oma [27]. We identified the 115-kDa HLTF wild-type
protein in cervical intraepithelial neoplasia I-III samples
by Western blotting, but only the truncated 83-kDa and
95-kDa proteins were detected in invasive squamous cell
carcinoma samples. The 83-kDa and 95-kDa proteins
have similar sizes to the HLTF variants Met1ΔA and
Met1ΔB, respectively, which were previously charac-
terized in HeLa cells and lack the domains that are
Figure 7 Detection of HLTF protein by immunofluorescence in 3 thyroid cancer cell lines and Immunodetection of HLTF on Western
Blot. The 3 thyroid cancer cell lines derived from human thyroid cancers: papillary carcinoma B-CPAP (A), follicular carcinoma FTC-133 (B) and
anaplastic carcinoma 8505C (C). HLTF was detected using the ART2 rabbit antiserum and revealed by a secondary antibody coupled to Alexa
Fluor as described in the Methods. The scale bar is 50 μm. (D-F) 40 μg (E and F) or 60 μg (D) of cell lysate (total [D], nuclear [E] and cytoplasmic
[F]) were analyzed by 4%-12% gradient PAGE-SDS. After protein transfer to a membrane, immunodetection was performed with the α-HLTF rabbit
serum (Sigma, 1/500 [E and F] and 1/1000 [D]) as described in Methods. Lane 1: TPC-1. Lane 2: B-CPAP. Lane 3: FTC-133. Lane 4: 8505C. Lane 5: HeLa.
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squamous-cell carcinomas [26], we also showed that
truncated HLTF protein variants increase during tumor
progression when comparing carcinomas to normal epi-
thelia or dysplasia and that HLTF overexpression was
associated with a worse prognosis.
Considering these data, we propose that these trun-
cated HLTF proteins, having lost important domains
that are involved in DNA repair, may contribute to thy-
rocyte progression in carcinogenesis.
Using immunocytochemistry on several thyroid cancer
cell lines, we visualized the HLTF protein exclusively in the
nucleus. Nevertheless, wild-type HLTF protein (115-kDa)
was present both in the nuclear and cytoplasmic compart-
ments in addition to a truncated form(s) (70-kDa, 83-kDa
and/or 95-kDa). Therefore, thyroid cancer cells might
utilize various mechanisms to suppress HLTF DNA repair
activity: i) mutations affecting the wild type protein activity
without excluding it from the nucleus; ii) mutations that
shift the end of the reading frame, causing truncated va-
riants; and iii) mutations that alter the nuclear localization
signal, causing HLTF exclusion from the nucleus. These
alterations could occur by alternative HLTF mRNA spli-
cing, as we have previously observed [26]. In this way,
these proteins are unable to perfom DNA repair, which
would provide an advantage to cell growth in cancer.Indeed, we have previously shown that truncated HLTF
variants are progressively overexpressed during carci-
nogenesis (head and neck cancer [26] as well as cervical
cancer [27]) and replace the wild-type protein. In the im-
munoblotting experiments presented here, we could not
discriminate one type of thyroid cancer from another be-
cause all of the cell lines shared the same expression profile
of HLTF protein forms. In this regard, van Staveren et al.
[28] and Saiselet et al. [29] have shown by mRNA profiling
studies that, regardless of where the cancer originated, thy-
roid cancer cell lines appear to be the most similar to ded-
ifferentiated thyroid cancer in vivo (anaplastic, the most
aggressive). Thus, these tumor cell lines are not reliable
in vitro tools for studying differentiated thyroid tumors be-
cause they have progressively acquired characteristics of
dedifferentiated cells in culture. However, these cells could
be used to identify genes involved in this process of tumor
dedifferentiation. Papillary and follicular thyroid cancer
cells may have lost their DNA synthesis/replication regula-
tion mechanisms during their in vitro cell adaptation, ac-
cording to the studies cited above [28,29].
Finally, we know that HLTF is implicated in post-
replication DNA repair, a mechanism that could be dis-
turbed in thyroid cancer cells [20]. To better understand
the role of HLTF in thyroid cancer progression, we
would like to study HLTF expression profiles, both at
Arcolia et al. BMC Cancer 2014, 14:492 Page 11 of 12
http://www.biomedcentral.com/1471-2407/14/492the mRNA level (by RT-PCR) to identify potential muta-
tions and at the protein level.
Conclusions
This study demonstrates a correlation between HLTF ex-
pression level and thyroid neoplastic progression. Nuclear
HLTF immunostaining may therefore represent a new
marker in thyroid tumors that could be used with FNA in
an attempt to better distinguish benign thyroid nodules
from malignant tumors. Three truncated HLTF forms
lacking the domains that are involved in DNA repair were
detected in thyroid carcinomas, strengthening the role of
HLTF as a tumor suppressor.
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